State Street Holds 4.7% Of Allogene Without Seeking To Influence Control

The September 30 holding covered 16.3 million shares; Allogene released initial autoimmune-treatment trial results Monday.

Share
State Street Holds 4.7% Of Allogene Without Seeking To Influence Control

State Street reported a 4.7% stake in Allogene Therapeutics, which develops donor-derived cell therapies for cancer and autoimmune diseases, in an SEC ownership filing Tuesday. The holding covered 16,326,197 common shares as of September 30, and State Street certified that it was not seeking to change or influence the company's control.

A Passive Stake With Shared Authority

State Street reported shared voting authority over 16,065,094 shares and shared authority to sell or otherwise dispose of all 16,326,197 shares in the position. It reported no sole voting or disposal authority.

The certification places the holding within State Street's ordinary business activities, rather than an effort to alter Allogene's control. The ownership report concerns a September 30 position, not a purchase dated to Monday's clinical announcement.

Autoimmune Results Carry A Safety Caveat

Allogene released initial clinical results Monday for ALLO-329, its experimental autoimmune-disease cell therapy. Eight of 10 patients with systemic sclerosis achieved meaningful improvement in a measure of skin thickening and sustained that improvement, the company said.

Every treated patient experienced an adverse event. The results concern an experimental treatment at a company that has no approved products.

Allogene's therapies use genetically engineered T cells from healthy donors, designed for use across patients rather than made individually for each recipient. Its core programs also include cema-cel for large B-cell lymphoma and ALLO-316 for renal cell carcinoma, a kidney cancer.

The company manufactures clinical-trial supplies at its Newark, California, facility. In its annual report for 2025, Allogene said it had treated more than 200 patients across six clinical studies and activated more than 60 sites for its pivotal ALPHA3 lymphoma trial.

Allogene's market value was $367 million as of Tuesday at 6:46 a.m. ET. State Street's reported ownership remains a September 30 holding, with no control agenda attached.

Sources

More on Allogene Therapeutics

All Allogene Therapeutics (ALLO) coverage →